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Approximately 20–40% of diabetic patients develop nephropathy which is the leading cause of ESRD in developed countries. The
ACE I/D polymorphism is thought to be amarker for functional polymorphismwhich regulates circulating and tissue ACE activity.
While the initial study found a protective effect of the II genotype on the development of nephropathy in IDDMpatients, subsequent
studies have addressed the role of ACE I/D polymorphism in the development and progression of diabetic nephropathy. RAAS
blockers are the first line drugs for the treatment hypertension associated with diabetes and have been widely used in everyday
clinical practice for the purpose of reducing proteinuria in patients with various renal diseases. However, the antiproteinuric effect
of RAAS blockers is variable and the percentage of reducing proteinuria is in the range of 20–80%. The antiproteinuric effect of
RAAS blockers may be related to a number of factors: the type or the dose of RAAS blockers, the duration of therapy, the level of
sodium intake, and the type of patient’s ACE I/D genotype. Besides the nongenetic factors, drug responses, can be influenced by
ACE gene polymorphism. In this review, we discuss the relationship between ACE I/D polymorphism and diabetic nephropathy
and therapeutic response of RAAS blockers.
1. Introduction
Chronic kidney disease (CKD) is a worldwide public health
problem that affects millions of people from all over the
world. Diabetic nephropathy is a common complication
in patients with diabetes and the leading cause of end-
stage renal disease (ESRD) [1]. Over the last decade, the
prevalence of diabetes has increased worldwide, as a result
of the continuous rise in type 2 diabetes incidence [2].
Approximately 20–40% of diabetic patients including IDDM
andNIDDMdevelop diabetic nephropathy.The pathogenesis
of this drastic complication is not clearly understood, but
available data suggests that multiple factors such as hemo-
dynamic alterations,metabolic abnormalities, various growth
factors, and genetic factors contribute to the pathogenesis of
diabetic nephropathy. In experimental and human diabetic
nephropathy, systemic and glomerular hypertension played
a role in the initiation and progression of nephropathy [3].
These hemodynamic changes may be explained in part by
alterations in the renin-angiotensin system. Consequently,
genes involved in the renin-angiotensin system have been
suggested as potential genetic predispositions for the devel-
opment of diabetic nephropathy. Many previous publica-
tions suggest that genetic predisposition plays a role in the
development of diabetic nephropathy which clusters within
families, both in type 1 (IDDM) and type 2 (NIDDM)diabetes
mellitus [4–7]. Polymorphism means the phenomenon of
having two or more genetic variants. DNA polymorphism,
so far, is known to exist for the great majority of human
genes. In diabetes mellitus, several models can be figured
out to represent different concepts of the pathogenesis of
diabetic nephropathy and to incorporate genetic factors
[8]. Angiotensin-I converting enzyme (ACE) is one of the
key enzymes in the renin-angiotensin-aldosterone system
(RAAS) and the insertion (I)/deletion (D) polymorphism of
this gene has been studied extensively with renal [9] and
cardiovascular [10] complications of diabetic nephropathy.
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2. Structure of ACE Gene and Its
Insertion/Deletion Polymorphism
The ACE, which was originally discovered in equine plasma,
is a membrane-bound dipeptidyl carboxypeptidase ectoen-
zyme located in the endothelial lining of blood vessels
throughout the body where it plays an important role in
proliferation of vascular smooth muscle cells through the
conversion of angiotensin-I to angiotensin II and bradykinin
inactivation [11]. The ACE is found as a membrane-bound
enzyme in endothelial cells and different types of epithelial
and neuroepithelial cells as well as in circulating form in
biological fluids, such as plasma, cerebrospinal fluid, amni-
otic fluid, and seminal fluids [11, 12]. The mechanisms that
lead to the biosynthesis of the circulating form of ACE
are unclear, but available data indicates that its structure
is very similar to that of the cellular form. The circulating
form is virtually identical to the cellular form except for the
lack of the transmembrane and intracellular sequence but
whether it arises from specific proteolytic cleavage from the
cell surface or nonspecifically from senescent cells has yet
to be determined [12]. ACE genes have been cloned in the
human, mouse, and rabbit and the enzyme was the product
of one gene inman [12, 13].The human andmouse genes were
made up of 26 exons and 25 introns. Most somatic forms of
ACE appear to be transcribed from all exons except exon 13
which encodes the unique N-terminal region of the testicular
form [12]. The human ACE gene was localized to the long
arm of chromosome 17. Cloning of the ACE gene had made
it possible to identify a 287 bp insertion/deletion polymor-
phism in intron 16 (ACE I/D polymorphism) that appears
to affect the level of serum ACE activity. The genotype with
deletion of the 287 base pair resulted in higher plasma ACE
levels [14].The plasma ACE was predominantly derived from
tissue vascular endothelial cells suggesting that patients with
the DD genotypemight have higher tissue angiotensin II [11].
Angiotensin II might modulate the growth of smooth muscle
cell and induce myointimal hyperplasia after endothelial
injury [15], and administration of ACE inhibitors prevented
myointimal proliferation after vascular injury [16].
3. Genetic Control of Plasma ACE Level
Plasma ACE concentrations are stable when measured
repeatedly in a normal subject [17] but large interindividual
variations make it difficult to interpret plasma ACE levels
in a given patient [11]. The study conducted in a large
sample of healthy families showed an intrafamilial resem-
blance between ACE levels and also suggested that they
were subject to the effect of major gene [18]. The ACE
I/D polymorphism accounts for over 40% of interindividual
variability of serum or tissue ACE activity [19]. Patients
homozygous for the deletion had the greatest serum ACE
activity, whereas those homozygous for the insertion had the
lowest level. An insertion/deletion (I/D) polymorphism of
intron 16 of the angiotensin-I converting enzyme (ACE) gene
is largely responsible for variations in plasma ACE levels and
for explaining approximately 50% of the variability in serum
ACE activity observed [14]. Using the linkage-segregation
analysis of the plasma ACE, Cambien [11] has shown that
the ACE I/D polymorphism was a marker for an unknown
functional polymorphism (ACE S/s) which appeared to be a
new independent risk factor for myocardial infarction.
4. ACE Insertion/Deletion Polymorphism and
the Development of Diabetic Nephropathy
The ACE I/D polymorphism is thought to be a marker for
functional polymorphism which regulates circulating and
tissue ACE activity [14, 18, 19]. Since 1990, its association with
diabetic nephropathy has been extensively investigated and
more than 300 studies have explored genetic associations of
this polymorphism in more than 100 conditions including
diabetic nephropathy [20]. Up to now, the I/D polymorphism
of ACE gene is the most extensively studied marker for
associationwith diabetic nephropathy.While the initial study
by Marre et al. [21] found a protective effect of the II
genotype on the development of nephropathy in IDDM
patients, subsequent studies have yielded inconsistent results.
Over the past decades, many studies have been conducted
to examine the association between ACE I/D polymorphism
and nephropathy in type 1 and type 2 diabetes, but the results
still remain inconsistent. However, recently conducted meta-
analysis showed consistent association between ACE D allele
or DD genotype and ESRD risk in diabetic nephropathy
patients. In 2005, Ng et al. [22] reported a meta-analysis
of 14727 diabetic patients including 47 studies (8,663 cases,
6,064 controls) from 1994 to 2004. They confirm a statis-
tically significant protective role of the II genotype in the
development of diabetic nephropathy; the effect was most
pronounced in Asians with type 2 diabetes, followed by
Caucasians with types 1 and 2 diabetes. They suggested that
these findings may have implications for the management of
diabetic nephropathy using ACE inhibitors especially among
type 2 diabetic Asians. In 2012, another meta-analysis was
reported by Wang et al. [23]. They conducted a comprehen-
sive meta-analysis on 63 published studies from 1994 to 2010
with 14,108 cases and 12,472 controls relating variants of the
ACE I/D polymorphism to the risk of developing diabetic
nephropathy.They included all of the studies that determined
the genotype distribution of ACE I/D polymorphism in cases
with type 1 or type 2 diabetes and nephropathy and in
diseased controls or in healthy controls. The overall analysis
showed a significant association between the ACE I/D poly-
morphism and the risk of diabetic nephropathy for all genetic
models (ID versus II: OR = 1.12, 95% CI 1.02–1.24; DD versus
II: OR = 1.27, 95% CI 1.13–1.44; allele contrast: OR = 1.15, 95%
CI 1.08–1.23; dominant model: OR = 1.18, 95% CI 1.07–1.31;
and recessive model: OR = 1.18, 95% CI 1.08–1.30, resp.). In
stratified analysis by ethnicity and diabetesmellitus type, they
further found that the Asian group with type 2 DM showed
a significant association for all genetic models (ID versus II:
OR = 1.25, 95% CI 1.07–1.47; DD versus II: OR = 1.57, 95% CI
1.24–1.98; allele contrast: OR = 1.30, 95% CI 1.15–1.46; domi-
nant model: OR = 1.37, 95%CI 1.10–1.69; and recessive model:
OR = 1.34, 95% CI 1.15–1.56, resp.). However, they failed to
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find any significant effects for different genetic models in
other subgroups. The authors suggested that the ACE I/D
polymorphismmay contribute to nephropathy development,
especially in the Asian group with type 2 diabetes mellitus.
5. ACE Insertion/Deletion Polymorphism
and the Progression of
Diabetic Nephropathy to ESRD
In 1996, Yoshida et al. [24] including 168 Japanese patients
with NIDDM followed over 10 years have shown that ACE
DD genotype has a high prognostic value for progressive
deterioration of renal function. They also showed that
patients with stable renal function had no significant differ-
ence in the distribution of ACE genotype between patients
with albuminuria and patients without albuminuria. Analysis
of the clinical course of the three ACE genotypes revealed
that themajority (95%) of patients with theDDgenotypewho
had albuminuria progressed to end-stage renal disease within
10 years of diagnosis of diabetes. Moreover, the ACE DD
genotype had the increased mortality in patients on dialysis
and the prevalence of the DD genotype in patients on chronic
dialysis decreases year by year. Next year, Schmidt et al. [25]
reported 658 Caucasian patients with type II diabetes, 347
without diabetic nephropathy and 311 with various stages of
diabetic nephropathy, anddetermined the I/Dpolymorphism
of the ACE gene. They compared patients at the extremes of
renal risk, that is, normotensive patients without antihyper-
tensive treatment and without nephropathy (𝑛 = 144) versus
patients on dialysis (𝑛 = 61), differedwith respect to genotype
(DD 36.8% versus 57.4%; 𝑃 = 0.007) and allele frequencies
(D 0.59 versus 0.76; 𝑃 < 0.001). In this study, patients with
the highest renal risk more frequently had the DD genotype.
This would be compatible with a greater risk of (or rate
of) progression to end-stage renal failure. Vleming et al.
[26] also compared the ACE genotype distributions in 79
Caucasian IDDMpatients with ESRD and 82 control patients
without microalbuminuria after fifteen years of IDDM. The
ACE genotype distribution in patients was not in accordance
with the Hardy-Weinberg equilibrium due to a significant
overrepresentation of the DD genotype (𝜒2 = 8.9, 𝑃 = 0.01).
The presence of the DD genotype increased the risk of end-
stage renal failure two-fold compared to the other genotypes
(odds ratio 2.1, 95% CI 1.1–4.0). They concluded that the risk
of end-stage renal failure in patients with IDDM is two-fold
increased in patients with the DD genotype as compared to
patients with other genotypes. We also studied the impact
of insertion/deletion (I/D) genotypes on the progression of
diabetic nephropathy in 239 Korean patients with type 2
diabetes (Group 1, 99 patients with stable renal function;
Group 2, 140 patients with declining renal function) [27].The
frequency of the DD genotype was significantly greater in
group 2 comparedwith group 1 (30.7% versus 9.1%;𝑃 < 0.05).
Patients with the DD genotype reached the end point (serum
creatinine > 2.0mg/dL [176.8micromol/L]) faster than those
with the other genotypes (DD, 11.38 ± 4.08 years; ID, 13.85
± 4.04 years; II, 14.04 ± 4.06 years, resp., 𝑃 < 0.05) and
took significantly less time to reach dialysis therapy (DD,
13.10 ± 4.45 years; ID, 16.21 ± 4.74 years; II, 15.13 ± 4.09
years, resp.,𝑃 < 0.05). Inmultiple logistic regression analysis,
systolic blood pressure and DD genotype showed significant
correlations with the progression of diabetic nephropathy.
In patients with the DD genotype, the odds ratio was 3.881
(95% confidence interval, 1.564 approximately 9.628; 𝑃 =
0.003) comparedwith that with the II genotype.We suggested
that the ACE DD genotype might be a significant risk factor
for the progression of diabetic nephropathy. Recently, Yu
et al. [28] published meta-analysis of 12 previous studies
containing 4,015 diabetic nephropathy patients (981 cases,
3,034 controls). In this study, they showed that in overall
populations, there was a notable association between D allele
or DD genotype and ESRD susceptibility (D: OR 1.32, 95%
CI 1.11–1.56, 𝑃 = 0.002; DD: OR 1.67, 95% CI: 1.25–2.21,
𝑃 = 0.004). In the subgroup analysis according to ethnicity,
D allele or DD genotype was associated with ESRD risk
in Asians. In Caucasians, the association of DD genotype
with ESRD risk was observed, but the D allele was not.
Furthermore, ACE I/D gene polymorphism was associated
with ESRD risk in patients with diabetic nephropathy due
to type 2 DM, but the association was not found for patients
with diabetic nephropathy due to type 1 DM.They concluded
that D allele or DD genotype is associated with the ESRD
susceptibility in diabetic nephropathy patients.
6. ACE I/D Polymorphism and Antiproteinuric
(Renoprotective) Responses to RAAS
Inhibitor Therapies in Diabetic
Nephropathy
Earlier studies repeatedly showed that patients with DD
genotype or D allele have elevated circulating and tissue
ACE activity [14, 19] compared to patients with I allele.
This may contribute to the interindividual variability in
the antiproteinuric responses to inhibition of the RAAS
using either ACE inhibitors (ACEIs) or angiotensin II type
1 receptor blockers (ARBs) [29]. RAAS blockers are the first-
line drugs for the treatment of hypertension associated with
diabetes in the fact that these drugs not only lower systemic
blood pressure but also reduce intraglomerular pressure.
Imanishi et al. [30] showed that the mechanism by which an
ACE inhibitor caused a short-term decrease in albuminuria
in early diabetic nephropathy involved a glomerular hemo-
dynamic change, namely, a decrease in intraglomerular cap-
illary pressure. These drugs have greatly improved the renal
prognosis and survival of diabetic patients with nephropathy
over the last decade [31]. However, despite therapy targeting
elevated blood pressure, albuminuria, hyperglycemia, and
lipid abnormalities, patients with diabetic nephropathy still
on average have a rate of decline in renal function three
to six times that seen in individuals without renal disease
[31, 32]. Consequently, diabetic nephropathy is still one of
the principal causes of end-stage renal disease, leading to
dialysis and death in developed countries. Although current
therapeutic strategies have alleviated the huge burden of
diabetic nephropathy, many patients still progress to ESRD.
One reason for the inadequacy of current antiproteinuric
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(renoprotective) therapy and the persistent poor renal prog-
nosis is the large interindividual variation in response to
first-line therapy including antihypertensive drugs blocking
the renin-angiotensin-aldosterone system [33]. Furthermore,
overt proteinuria seen in diabetic nephropathy is itself a risk
factor thatmay adversely affect renal function, and it is associ-
ated with a faster rate of renal disease progression.Therefore,
the reduction of proteinuria is an important tool for retarding
the progression of renal disease in diabetic nephropathy
patients [34]. Traditionally, ACE inhibitors (ACEIs) and
angiotensin II type 1 receptor blockers (ARBs) have been
widely used in everyday clinical practice of nephrology
for the purpose of reducing proteinuria in patients with
various renal diseases including diabetes mellitus. However,
the antiproteinuric effect of ACE inhibitors on proteinuria is
variable and the percentage of reducing proteinuria is in the
range of 20–80% in a variety of renal diseases [35–37]. The
antiproteinuric effect of ACE inhibitors and/or angiotensin
II type 1 receptor blockers may be related to a number of
factors: the type or dose of the RAAS blockers, the duration
of therapy, the level of sodium intake, and the type of patient’s
ACE genotype [29, 38–40]. The antiproteinuric mechanisms
of RAAS blockers are thought to decrease intraglomerular
capillary pressure by reducing both afferent and efferent renal
arteriolar resistance, predominantly dilating efferent arteriole
and systemic blood pressure [41, 42]. As demonstrated in
previous studies, RAAS blockade has been superior to other
antihypertensive agents in reducing albuminuria and slowing
rate of decline inGFR despite similar blood pressure controls.
Besides the nongenetic factors, drug responses are also influ-
enced by inherited factors such as ACE gene polymorphism.
The basic concept of pharmacogenomics is a drug interacting
with its target, for instance, an enzyme or a receptor. When
genetic polymorphism leads to modified target availability or
function, the drug response is modified as well [43]. It has
been reported that ACE I/D genotypes appeared to be amajor
determinant of plasma and tissue ACE activities [14, 18, 19].
Individuals with the DD genotype have the greatest and those
with II genotype have the least ACE concentrations. So, it
is expected that the differences in plasma and tissue ACE
activities associated with ACE I/D genotype might affect the
antiproteinuric (renoprotective) responses to RAAS inhibi-
tion. Several studies concerning antiproteinuric (renoprotec-
tive) effect of RAAS blockers and ACE I/D polymorphism
in diabetic nephropathy were reported so far [34, 44–53].
However, the antiproteinuric (renoprotective) effect of RAAS
blockers and ACE I/D genotype in diabetic nephropathy
is inconclusive. These results may be due to incomplete
blockade of RAAS by suboptimal doses and/or compen-
satory mechanisms occurring during long-term treatment
with RAAS blockers. After initiation of ACEI treatment,
angiotensin II level in plasma is lowered initially. However,
during long-term treatment of ACEI, angiotensin II level
tends to increase as a result of ACE escape and angiotensin
II generation through non-ACE dependent pathways such
as chymase or other serine proteases. Incomplete RAAS
blockade during chronic ACEI therapy may be overcome
by inhibiting the action of angiotensin II at the site of the
angiotensin II type 1 receptor by an ARB. On the contrary, in
treatment with ARB, there also tends to be a compensatory
increase in renin and angiotensin II levels, thereby increasing
the competition at the angiotensin II type 1 receptor site.
So, in this situation, we can reduce compensatory increased
angiotensin II by adding ACEI.
6.1. ACE Inhibitors and ACE I/D Polymorphism. Several
previous studies suggested that ACE genotype may predict
the response of patients to antiproteinuric and renoprotective
effect with ACE inhibitors (ACEIs). Parving et al. [44], in
their observational followup study of type 1 diabetic patients
with diabetic nephropathy receiving ACE inhibitor captopril
(𝑛 = 35 and 𝑛 = 169), have reported that the DD
genotype reduces the long-term beneficial effect of ACE
inhibition on the progression of diabetic nephropathy in
patients with IDDM. Jacobsen et al. [45] tested the potential
role of ACE I/D polymorphism on the early antiproteinuric
responsiveness in an observational followup study with sixty
young hypertensive type 1 DM nephropathy patients. They
showed more albuminuria reduction with captopril therapy
in II genotype than in ID or in DD genotypes. Data from a
EURODIAB randomized controlled trial lisinopril in IDDM
[46] showed that the I/D polymorphism of the ACE gene
modulates the therapeutic effect of ACE inhibition on the
progression of urinary albumin excretion in IDDM patients.
Patients with the II genotype showed the fastest rate of AER
progression on placebo but had an enhanced response to
lisinopril. Albumin excretion rate (AER) at 2 years (adjusted
for baseline AER) was 51.3% lower on lisinopril than placebo
in the II genotype patients (95% CI, 15.7 to 71.8; 𝑃 = 0.01),
14.8% lower in the ID group (–7.8 to 32.7; 𝑃 = 0.2), and
7.7% lower in the DD group (–36.6 to 37.6; 𝑃 = 0.7). Only
in the II group the difference was statistically significant even
after adjustment for gender, baseline and followup BP, and
metabolic control. The authors concluded that knowledge
of ACE genotype may be of value in determining the likely
impact of ACE inhibitor treatment on the albuminuria
reduction. Another study from Jacobsen et al. [47], which
included 169 IDDMpatients with overt nephropathy, showed
that the D allele of the ACE I/D polymorphism in addi-
tion to nongenetic risk factors independently accelerated
progression of diabetic nephropathy during ACE inhibition.
Also, in this study of patients with type 1 diabetes, the I
allele was associated with a slower progression to doubling of
serum creatinine or ESRD. Taken together, in type 1 diabetes
with nephropathy, the I allele increases the responsiveness to
the antiproteinuric (renoprotective) effect of ACE inhibitor
therapy. Data in type 2 DM nephropathy in relation to
ACE I/D polymorphism and antiproteinuric (renoprotective)
effect of ACE inhibitors are scarce. Our group investigated
the antiproteinuric effect of ACE inhibition (benazepril
10mg/day or perindopril 4mg/day) in relation to ACE I/D
polymorphism in a short-term observational followup study
in 83 NIDDM patients with overt nephropathy (urinary pro-
tein excretion over 500mg/day) classified into three groups
in accordance with ACE genotypes (17 DD; 33 ID; 33 II)
and prospectively followed up for 3 months [34]. Before
entry, previously used ACE inhibitors were withdrawn for at
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Table 1: Studies examining the association of the ACE I/D polymorphism and response to antiproteinuric (renoprotective) effect of ACE
inhibitor therapy.
Authors
(year) Ethnicity
Disease and
patient
number
Study durations
(month)
Therapy
drug
Effects on proteinuria or
progression Reference
Parving et al.
(1996) Caucasian Type 1DM (35) 84 Captopril
Faster progression and higher
residual proteinuria in DD
genotype
[44]
Jacobsen et al.
(1998) Caucasian
Type 1DM
(60) 6 Captopril
II genotype more
albuminuria reduction [45]
Penno et al. (1998) Caucasian Type 1DM(530) 24 Lisinopril
II genotype more
albuminuria reduction [46]
Jacobsen et al.
(2003) Caucasian
Type 1DM
(169) 72
ACEIs (captopril,
lisinopril, and
enalapril)
D Allele accelerated
progression of DMN [47]
Ha et al. (2000) Asian(Korean)
Type 2DM
(83) 3
Benazepril,
perindopril
DD genotype more
albuminuria reduction [34]
So et al. (2006) Asian(Chinese)
Type 2DM
(2089) 44.6 RAAS inhibitors
DD genotype higher risk of
declining renal function [48]
Cheema et al.
(2013)
Asian
(Indian)
Type 2DM
(490) 36 ACEIs
II genotype better
renoprotective effect [49]
ACE: angiotensin converting enzyme; ACEI: angiotensin converting enzyme inhibitor; ACE I/D polymorphism: angiotensin converting enzyme inser-
tion/deletion polymorphism.
least 2 weeks and baseline proteinuria was measured. Our
study showed that the percentage reduction in proteinuria
for DD genotype was significantly higher than in ID and
in II genotypes (50.9 ± 19.2% versus 19.2 ± 16.0%, 20.2 ±
20.4%, 𝑃 < 0.05). There were no statistically significant
correlations between the levels of baseline proteinuria and
the magnitudes of the reduction of proteinuria under ACE
inhibition (𝑃 > 0.05). These results indicated that ACE
DD genotype is more susceptible than ACE II and ID
genotypes to the antiproteinuric effect of ACE inhibitors.
However, this investigation had small subjects and short-term
followup period. Another study by So et al. [48] provided
more evidence supporting the importance of II genotype
in response to ACE inhibition. They found that, in 2089
Chinese patients with normoalbuminuria, microalbumin-
uria, or macroalbuminuria over a median period of 44.6
months, ACE inhibitor therapy decreasedmortality and renal
end point which was defined as death due to renal failure,
dialysis, eGFR of <15mL/min/1.73m2 or more than 50% loss
of eGFR, more effectively in I allele carriers than in DD.This
study was the only study in type 2 diabetes with adequate
power and followup. However, we have to be cautious in
interpreting this finding because the favorable effects of the
I allele were restricted to those with normoalbuminuria
or microalbuminuria. Another study regarding RAAS gene
polymorphisms and renal responsiveness to RAAS inhibition
in type 2 diabetic Asian Indians was reported recently by
Cheema et al. [49] from India. They enrolled 810 north
Indian type 2 diabetics treated with ACE inhibitor or ARB
and were followed up for 3 years. They observed that the
ACE II genotype and cumulative genetic risk score of < 1
was associated with better renoprotective response to ACE
inhibitor in type 2 DM with normoalbuminuria. However,
there was no significant difference in renoprotective effect
in type 2 diabetics with nephropathy based on ACE I/D
genotypes with 3-year ACE inhibitor therapy (Table 1).
6.2. Angiotensin II Type 1 Receptor Blockers and ACE I/D Poly-
morphism. Data on angiotensin II type 1 receptor blocker
(ARB) in relation toACE I/Dpolymorphism and antiprotein-
uric (renoprotective) effects in type 1 diabetes with nephropa-
thy are also scarce. Two small studies by Andersen et al.
[50, 51] were found in the literatures. They showed that the
antiproteinuric effect of 36- and 4-month ARB (losartan) had
similar beneficial renoprotective and antiproteinuric effect
in 54 hypertensive white type 1 DM nephropathy patients
with ACE II and DD genotypes. Same result was reported by
Haneda et al. [52] in 127 Japanese type 2 DM nephropathy
patients. They found that ARB (candesartan) is useful in
reducing proteinuria in type 2 DM nephropathy patients
compared with placebo and seems to be effective in subjects
with both the II and DD genotypes of the ACE gene. More
data on the interactions betweenACE I/Dpolymorphism and
ARB therapy have been provided by analyses of theReduction
of Endpoints in NIDDM with the AII Antagonist Losartan
(RENAAL) study, a double blind, multicenter, prospective,
randomized, and placebo controlled clinical trial designed to
evaluate the renal effects of losartan in 1513 type 2 diabetic
patients with overt nephropathy [53]. ACE I/D data were
available in 1435 of the 1513 RENAAL study patients. Available
ACE I/D data showed that compared with placebo losartan
reduced the risk of reaching the composite end point of
doubling of serum creatinine, ESRD, or death by 5.8%, 17.6%,
and 27.9% among those with the II, ID, and DD genotypes,
respectively. This study demonstrated that the deletion allele
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Table 2: Studies examining the association of the ACE I/D polymorphism and response to antiproteinuric (renoprotective) effect of ARB
therapy.
Authors
(Year) Ethnicity
Disease and patient
number
Study durations
(month)
Therapy
drug
Effects on proteinuria or
progression
Reference
Andersen et al. (2002) Caucasian Type 1DM (54) 4 Losartan No differences inreduction of proteinuria
[50]
Andersen et al. (2003) Caucasian Type 1DM (54) 36 Losartan No differences inreduction of proteinuria
[51]
Haneda et al. (2004) Asian(Japanese) Type 2DM (127) 3 Candesartan
No differences in
reduction of proteinuria
[52]
Parving et al. (2008) Mixed Type 2DM (1435) 40.8 Losartan
DD genotype more risk
reduction reaching
ESRD
[53]
Cheema et al. (2013) Asian(Indian) Type 2DM (320) 36 ARBs
DD genotype associated
with better
renoprotective response
[49]
ARB: angiotensin receptor blocker; ACE I/D polymorphism: angiotensin converting enzyme insertion/deletion polymorphism.
of the ACE gene had a harmful impact on the composite
endpoint. The beneficial effects of losartan were greatest in
the ACE DD genotype group and intermediate in the ACE
ID genotype group for nearly all endpoints.The novel clinical
importance of this study is that those patients who have the
greatest need for renoprotective treatment have the best effect
of losartan (DD and ID genotype), whereas those patients
with a better renal prognosis (II genotype) also derived renal
benefit. This is the largest, double blind randomized study
with adequate statistical power. However, several limitations
exist in this study. First, this is the largest trial evaluating the
association of the ACE/ID polymorphism on renal outcome
anddeath during angiotensin II-receptor blockade in diabetic
nephropathy; the studymaywell be underpowered in relation
to the individual components of composite endpoint. Second,
the ID alleles were not in Hardy-Weinberg equilibrium in
the black patients. Lastly, despite randomization, higher
baseline proteinuria was present in the II genotype in the
losartan group. In spite of the several limitations of this study,
the deletion allele of the ACE I/D polymorphism showed
unfavorable renal prognosis in patients with proteinuric type
2 diabetes, which can be improved by losartan treatment.
Another recent study by Cheema et al. [49] also reported
that, in type 2 diabetics with nephropathy, ACEDD genotype
and a genetic risk score of >6 were associated with better
renoprotective response to ARB. They suggested that ACE
I/D genotypes individually and in interaction with other
RAS single nucleotide polymorphisms (angiotensinogen and
angiotensin II type 1 receptor gene) modulate renoprotective
efficacy of ACE inhibitor and ARB in type 2 diabetics
depending on the status of proteinuria (Table 2).
7. Conclusions
The association between the RAAS activation and the devel-
opment and progression of diabetic nephropathy has been
known for a long period of time. ACE is the key enzyme of the
RAAS-cascade that plays a central role of blood pressure reg-
ulation and volumehomeostasis in the body.Despite the large
amount of studies looking for candidate genes, the ACE I/D
polymorphism remains the unique and well-characterized
locus clearly associated with development and progression
of diabetic nephropathy. After the initial study by Marre et
al. [21], numerous studies have addressed the role of ACE
I/D polymorphism in the development and progression of
diabetic nephropathy.Data reported so far showed that (1) the
ACE I/D polymorphism directly influences circulating levels
of ACE, (2) the II genotype protects against the development
of diabetic nephropathy, (3) the DD genotype predicts poor
renal response to RAAS inhibitors (the current strategy of
RAAS inhibition in patients with the DD genotype may be
insufficient to block an activated RAAS), and (4) angiotensin
II type 1 receptor blockers (ARBs) can ameliorate the adverse
effect of the D allele (no difference between genotypes is
observed when patients are treated with an ARB). Evaluating
the ACE I/D polymorphism in diabetic nephropathy is a
reliable tool to identify diabetic patients at risk and identify
patients who may benefit from antiproteinuric (renoprotec-
tive) therapy with ACE inhibitors and/or ARBs. This may
guide pharmacologic therapy in individual patients and help
to identify the patients with more aggressive use of RAAS
blockers such as supramaximal dose of individual RAAS
blocker and double or triple blockade of the RAAS. In case of
an insufficient response to RAAS blockers, we also consider
other treatment strategies such as glycemic control, low salt
intake, more aggressive proteinuria reduction strategy, and
hypercholesterolemia control that halt progression of diabetic
nephropathy.
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